M? Anton

Vivia Biotech

ViviaBiotech pioneers scale systems biology screening directly in patient samples, systematically searching for new indications of known drugs (reprofiling) in Hematological Cancers (HC) and Autoimmune Disorders, based on the first platform technology (PharmaFlow) capable of screening thousands of drugs (or combinations) directly on a patient's sample while it is still fresh (24/48 hours). Analyzing the effect of drugs in the live biological system where the disease operates enables Vivia to identify novel mechanism of action of existing drugs never before observed. With this innovative approach, Vivia has identified in less than a year several non-cytotoxic known drugs with proven safety profiles in humans, that kill selectively malignant cells ex vivo with better efficacy as the approved cytotoxics used in the treatment of several Hematological Cancers. Among those it has selected a lead compound that expects to enter clinical trials in Chronic Lymphocytic Leukemia .